42
Participants
Start Date
October 17, 2020
Primary Completion Date
July 13, 2023
Study Completion Date
August 8, 2023
FT538
Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell
Cyclophosphamide
Lympho-conditioning Agent
Fludarabine
Lympho-conditioning Agent
Daratumumab
Monoclonal Antibody, CD38, Anti-CD38
Elotuzumab
Monoclonal Antibody
Memorial Sloan Kettering Cancer Center, New York
Sarah Cannon Research Institute at Tennessee Oncology, Nashville
University of Minnesota Masonic Cancer Center, Minneapolis
Washington University, St Louis
MD Anderson Cancer Center, Houston
Texas Transplant Institute, San Antonio
St. David's South Austin Medical Center, Austin
Colorado Blood Cancer Institute, Denver
Lead Sponsor
Fate Therapeutics
INDUSTRY